| 13 | HEPATITIS C VIRUS (HCV) INFECTION EVALUATION OF PREVALENCE AND RELATED COSTS IN THE LOCAL HEALTH UNIT N.2, DISTRICT OF TREVISO
1)Bellin A.. 2)Giusti P.. 3)Schiavon A.. 4)Franchin G.. 5)Bettiol A.. 6)Bolcato J.. 7)Pirolo R.. 8)Chinellato A.. |
| 37 | CLINICAL PHARMACOLOGICAL ADVICE (CPA) FOR OPTIMIZATION OF LINEZOLID THERAPY IN HOSPITALIZED PATIENTS WITH MULTIDRUG RESISTANT GRAM-POSITIVE INFECTIONS
1)Cojutti P.. 2)Pea F.. 3)Merelli M.. 4)Bassetti M.. 5)Baraldo M.. |
| 63 | Interactions between antiretroviral drugs and human Arginase 1.
1)Lisi L. 2)Pizzoferrato M. 3)Miscioscia F. 4)Topai A. 5)Navarra P. |
| 77 | Healthcare resources use in patients with Human Virus Infection (HIV). Real-world evidence from Italian administrative databases.
1)P V. 2)S D. 3)B S. 4)De L. |
| 78 | Burden of comorbidities in HCV patients only and HIV-HCV co-infected patients in a real- world setting: retrospective study.
1)P V. 2)S D. 3)B S. 4)De L. |
| 121 | A NEW UHPLC-MS/MS METHOD FOR THE EVALUATION OF THE INTRACELLULAR PHARMACOKINETIC OF THE NEW DIRECT ANTIVIRAL AGENTS (DAA) IN HCV POSITIVE PATIENTS SAMPLES
1)Ariaudo A. 2)Favata F. 3)Boglione L. 4)Gontero E. 5)De nicolò A. 6)Carcieri C. 7)Simiele M. 8)Cusato J. 9)Di perri G. 10)D'avolio A. |
| 236 | In vitro and in vivo antibacterial activity of novel dual bacterial DNA type II topoisomerase inhibitors (NBTIs)
1)di Matteo A. 2)D'Atanasio N. 3)Apicella C. 4)Ombrato R. 5)Magarò G. 6)Milanese C. 7)Di Giorgio FP. 8)Tongiani S. |
| 323 | Pharmacokinetics of darunavir/cobicistat in an Italian observational, multicenter, prospective study (The STart Of REzolsta "ST.O.RE" study - TMC114FD1HTX4003).
1)Gori A. 2)Focà E. 3)Antinori A. 4)Vergori A. 5)Maserati R. 6)Rusconi S. 7)Di cristo V. 8)Uglietti A. 9)Termini R. 10)Mancusi D. |
| 350 | miRNA-218 TARGETS LIPIN-1 AND GLUT-4 GENES IN LOPINAVIR/RITONAVIR TREATED 3T3-L1 CELLS
1)Molteni L. 2)Bresciani E. 3)Saletti C. 4)Squillace N. 5)Torsello A. 6)Rizzi L. 7)Gori A. 8)Locatelli V. |
